FARE Clinical Network (FCN) - Apply for Membership

Since its founding in 2015, incredible progress has been made through the FARE Clinical Network (FCN), advancing knowledge and treatment, while improving the quality of life for 32 million people impacted by food allergies. 

As the world’s leading food allergy advocacy organization and the largest private funder of food allergy research, Food Allergy Research & Education (FARE) is developing FCN 2.0, a next-generation patient care and research model that will deliver a constant flow of improved research and solutions for patients and their families. 

As the natural successor to FCN, FCN 2.0 is the foundation from which all food allergy research will be conducted. The novel and innovative structure will empower a new, more sophisticated network to collaborate and advance the research sector’s work at a rapid pace. 

FCN 2.0 will establish a baseline understanding of the disease, elevate the quality-of and access-to care, strengthen the professional pathway for clinicians and scientist to enter food allergy care and research, expand the number of therapies by reducing barriers to development, and accelerate the time from lab discovery to human testing and daily care delivery. 

Based on extensive research and conversations with leading food allergy stakeholders, FARE is creating a new clinical network that maximizes the impact and role of the food allergy centers of excellence in the FARE Clinical Network:

  • Discovery Centers (up to 10 designated sites): A truly collaborative research network conducting the most cutting-edge clinical and translational research. Independently operated but expanding opportunities to work collaboratively with NIH sponsored networks. Will discover novel treatments, diagnostics, preventions and cures using the most advanced science and technology available. 
  • Clinical Centers (up to 30 designated sites): The world’s leading food allergy clinical trial network. Fast, high-quality, food allergy trials conforming to FARE-approved SOPs. They conduct a high volume of food allergy trials focused on therapeutics, diagnostics, clinical interventions, and coordinated with industry, NIH, FDA. 
  • Care Centers: Responsible for the delivery of tertiary care and serve as leaders in community education and training.

FCN 2.0 is a competitive process open to all sites, present and new, that meet the requirements (see FCN 2.0 application for details). The goal is to retain the most successful FCN sites and add new sites that enhance the overall function of the network to provide excellent care to patients with food allergies, and to assist in the conduct of basic, clinical and translational research in food allergy. 

The high-level objective is for FCN 2.0 to be a robust collaboration of research centers that conduct studies on all aspects of food allergy while providing patients with the latest diagnostic and therapeutic options as well as education and support.

To participate in FCN 2.0 – and be designated as an FCN 2.0 Discovery Center, Clinical Center or Care Center – organizations must complete and submit an FCN 2.0 Application no later than December 31, 2019. Awards will be announced in April and FNC 2.0 will be operational in July. 

Additional, specific details for the application process and resulting awards are included in the application package.